Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Core Insights - Zymeworks Inc. has achieved a $14 million cash research milestone from GSK related to a clinical milestone [1] - The collaboration with GSK includes potential milestone payments of up to$1.1 billion and tiered royalties on worldwide sales [3] Collaboration with GSK - Zymeworks entered into a technology transfer and license agreement with GSK in April 2016 to develop bispecific antibodies using the Azymetric™ platform [2] - The agreement was expanded in May 2019 to include access to Zymeworks' heavy-light chain pairing technology [2] Azymetric™ Platform - The Azymetric™ platform allows for the engineering of heterodimeric antibodies that can bind to multiple targets, providing unique mechanisms of action [4] - This technology enables the development of bispecific and trispecific antibodies, potentially overcoming therapeutic barriers [4] Clinical Validation - The Azymetric platform's clinical validation is highlighted by the accelerated approval of Ziihera® (zanidatamab-hrii) for advanced HER2-positive biliary tract cancer by the FDA in 2024 [5] Company Overview - Zymeworks is focused on developing multifunctional biotherapeutics for difficult-to-treat conditions, including cancer and autoimmune diseases [6] - The company has a robust pipeline, with ongoing clinical trials for multiple product candidates and plans for new investigational drug applications in 2025 [6]